BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27748860)

  • 1. Bone morphogenetic protein‑9 promotes the differentiation of mouse spleen macrophages into osteoclasts via the ALK1 receptor and ERK 1/2 pathways in vitro.
    Li H; Zhao D; Wang S; Ding J; Zhao L
    Mol Med Rep; 2016 Nov; 14(5):4545-4550. PubMed ID: 27748860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
    Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
    Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum/glucocorticoid-regulated kinase 1 as a novel transcriptional target of bone morphogenetic protein-ALK1 receptor signaling in vascular endothelial cells.
    Araki M; Hisamitsu T; Kinugasa-Katayama Y; Tanaka T; Harada Y; Nakao S; Hanada S; Ishii S; Fujita M; Kawamura T; Saito Y; Nishiyama K; Watanabe Y; Nakagawa O
    Angiogenesis; 2018 May; 21(2):415-423. PubMed ID: 29478089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMP9 Induces Cord Blood-Derived Endothelial Progenitor Cell Differentiation and Ischemic Neovascularization via ALK1.
    Kim J; Kim M; Jeong Y; Lee WB; Park H; Kwon JY; Kim YM; Hwang D; Kwon YG
    Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2020-31. PubMed ID: 26229139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells.
    Luo J; Tang M; Huang J; He BC; Gao JL; Chen L; Zuo GW; Zhang W; Luo Q; Shi Q; Zhang BQ; Bi Y; Luo X; Jiang W; Su Y; Shen J; Kim SH; Huang E; Gao Y; Zhou JZ; Yang K; Luu HH; Pan X; Haydon RC; Deng ZL; He TC
    J Biol Chem; 2010 Sep; 285(38):29588-98. PubMed ID: 20628059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of bone morphogenetic protein 9 (BMP9) as a novel profibrotic factor in vitro.
    Muñoz-Félix JM; Cuesta C; Perretta-Tejedor N; Subileau M; López-Hernández FJ; López-Novoa JM; Martínez-Salgado C
    Cell Signal; 2016 Sep; 28(9):1252-1261. PubMed ID: 27208502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2.
    Song T; Wang W; Xu J; Zhao D; Dong Q; Li L; Yang X; Duan X; Liang Y; Xiao Y; Wang J; He J; Tang M; Wang J; Luo J
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1639-46. PubMed ID: 23680673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
    Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
    Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone Remodeling.
    Zhou YM; Yang YY; Jing YX; Yuan TJ; Sun LH; Tao B; Liu JM; Zhao HY
    J Bone Miner Res; 2020 May; 35(5):978-993. PubMed ID: 31914211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
    Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
    Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
    Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
    Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsed electromagnetic fields inhibit osteoclast differentiation in RAW264.7 macrophages via suppression of the protein kinase B/mammalian target of rapamycin signaling pathway.
    Lei Y; Su J; Xu H; Yu Q; Zhao M; Tian J
    Mol Med Rep; 2018 Jul; 18(1):447-454. PubMed ID: 29749519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
    Kim JH; Peacock MR; George SC; Hughes CC
    Angiogenesis; 2012 Sep; 15(3):497-509. PubMed ID: 22622516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.